KRAS and neoplasm: Margonis et al. developed the genetic and morphological evaluation (GAME) score, which allocated scoring as follows: KRAS mutated tumours: 1 point; carcinoembryonic antigen (CEA) ≥20 ng/mL: 1 point; primary tumour lymph node metastasis: 1 point; ≤ tumour burden score (TBS) < 9: 1 point or TBS ≥ 9: 2 points; and extrahepatic disease: 2 points [53].